Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

In the treatment of chronic hepatitis C (CHC) protease inhibitors (PI) are actively used. The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and relapsers.Material and methods. Analysis of the cost...

詳細記述

保存先:
書誌詳細
主要な著者: D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin
フォーマット: Artigo
言語:Russo
出版事項: Journal Infectology 2016-11-01
シリーズ:Žurnal Infektologii
主題:
chronic hepatitis c
naive patients
relapse
simeprevir
narlaprevir
cost-effectiveness
オンライン･アクセス:https://journal.niidi.ru/jofin/article/view/514
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料